Bradley L. Campbell - Jan 2, 2024 Form 4 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Signature
/s/ Christian Formica, Attorney-in-Fact
Stock symbol
FOLD
Transactions as of
Jan 2, 2024
Transactions value $
-$839,655
Form type
4
Date filed
1/4/2024, 06:35 PM
Previous filing
Dec 19, 2023
Next filing
Jan 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FOLD Common Stock Award $0 +154K +19% $0.00 963K Jan 2, 2024 Direct F1
transaction FOLD Common Stock Tax liability -$220K -15.5K -1.6% $14.24 948K Jan 2, 2024 Direct
transaction FOLD Common Stock Options Exercise $64.6K +7.5K +0.79% $8.61 955K Jan 2, 2024 Direct
transaction FOLD Common Stock Sale -$107K -7.5K -0.79% $14.24 948K Jan 2, 2024 Direct F2
transaction FOLD Common Stock Options Exercise $102K +8.33K +0.88% $12.28 956K Jan 2, 2024 Direct
transaction FOLD Common Stock Sale -$119K -8.33K -0.87% $14.23 948K Jan 2, 2024 Direct F3
transaction FOLD Common Stock Tax liability -$561K -41.5K -4.38% $13.53 906K Jan 3, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FOLD Stock Options (right to buy) Award $0 +266K $0.00 266K Jan 2, 2024 Common Stock 266K $14.24 Direct F4
transaction FOLD Stock Options (right to buy) Options Exercise $0 -7.5K -8.33% $0.00 82.5K Jan 2, 2024 Common Stock 7.5K $8.61 Direct F5
transaction FOLD Stock Options (right to buy) Options Exercise $0 -8.33K -8.33% $0.00 91.7K Jan 2, 2024 Common Stock 8.33K $12.28 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in four equal annual installments beginning on January 2, 2025 and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock.
F2 This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.96 to $14.49 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.95 to $14.52 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter.
F5 All of the options were fully vested and exercisable as of the transaction date.

Remarks:

All transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2023.